380 related articles for article (PubMed ID: 16333527)
21. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.
Jordan NJ; Gee JM; Barrow D; Wakeling AE; Nicholson RI
Breast Cancer Res Treat; 2004 Sep; 87(2):167-80. PubMed ID: 15377841
[TBL] [Abstract][Full Text] [Related]
22. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
[TBL] [Abstract][Full Text] [Related]
23. (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells.
Farabegoli F; Papi A; Orlandi M
Biosci Rep; 2011 Apr; 31(2):99-108. PubMed ID: 20446926
[TBL] [Abstract][Full Text] [Related]
24. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling.
Normanno N; Campiglio M; Maiello MR; De Luca A; Mancino M; Gallo M; D'Alessio A; Menard S
Breast Cancer Res Treat; 2008 Nov; 112(1):25-33. PubMed ID: 18060492
[TBL] [Abstract][Full Text] [Related]
25. Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways.
Lai YH; Chen MH; Lin SY; Lin SY; Wong YH; Yu SL; Chen HW; Yang CH; Chang GC; Chen JJ
Oncotarget; 2015 Sep; 6(28):26252-65. PubMed ID: 26312766
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
[TBL] [Abstract][Full Text] [Related]
27. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.
Chen Y; Alvarez EA; Azzam D; Wander SA; Guggisberg N; Jordà M; Ju Z; Hennessy BT; Slingerland JM
Breast Cancer Res Treat; 2011 Jul; 128(1):69-78. PubMed ID: 20669046
[TBL] [Abstract][Full Text] [Related]
28. HPW-RX40 restores anoikis sensitivity of human breast cancer cells by inhibiting integrin/FAK signaling.
Chen IH; Shih HC; Hsieh PW; Chang FR; Wu YC; Wu CC
Toxicol Appl Pharmacol; 2015 Dec; 289(2):330-40. PubMed ID: 26386190
[TBL] [Abstract][Full Text] [Related]
29. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
[TBL] [Abstract][Full Text] [Related]
30. Tamoxifen treatment promotes phosphorylation of the adhesion molecules, p130Cas/BCAR1, FAK and Src, via an adhesion-dependent pathway.
Cowell LN; Graham JD; Bouton AH; Clarke CL; O'Neill GM
Oncogene; 2006 Dec; 25(58):7597-607. PubMed ID: 16799644
[TBL] [Abstract][Full Text] [Related]
31. Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions.
Hiscox S; Jordan NJ; Jiang W; Harper M; McClelland R; Smith C; Nicholson RI
Endocr Relat Cancer; 2006 Dec; 13(4):1085-99. PubMed ID: 17158755
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J
BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365
[TBL] [Abstract][Full Text] [Related]
33. TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR.
Golubovskaya VM; Virnig C; Cance WG
Mol Carcinog; 2008 Mar; 47(3):222-34. PubMed ID: 17849451
[TBL] [Abstract][Full Text] [Related]
34. Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically.
Morgan L; Gee J; Pumford S; Farrow L; Finlay P; Robertson J; Ellis I; Kawakatsu H; Nicholson R; Hiscox S
Cancer Biol Ther; 2009 Aug; 8(16):1550-8. PubMed ID: 19830888
[TBL] [Abstract][Full Text] [Related]
35. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
Formisano L; Nappi L; Rosa R; Marciano R; D'Amato C; D'Amato V; Damiano V; Raimondo L; Iommelli F; Scorziello A; Troncone G; Veneziani B; Parsons SJ; De Placido S; Bianco R
Breast Cancer Res; 2014 May; 16(3):R45. PubMed ID: 24887236
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of aqueous extracts of Taraxacum officinale on growth and invasion of breast and prostate cancer cells.
Sigstedt SC; Hooten CJ; Callewaert MC; Jenkins AR; Romero AE; Pullin MJ; Kornienko A; Lowrey TK; Slambrouck SV; Steelant WF
Int J Oncol; 2008 May; 32(5):1085-90. PubMed ID: 18425335
[TBL] [Abstract][Full Text] [Related]
37. Angiotensin II induces focal adhesion kinase/paxillin phosphorylation and cell migration in human umbilical vein endothelial cells.
Montiel M; de la Blanca EP; Jiménez E
Biochem Biophys Res Commun; 2005 Feb; 327(4):971-8. PubMed ID: 15652490
[TBL] [Abstract][Full Text] [Related]
38. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
[TBL] [Abstract][Full Text] [Related]
39. Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness.
Behmoaram E; Bijian K; Jie S; Xu Y; Darnel A; Bismar TA; Alaoui-Jamali MA
Am J Pathol; 2008 Nov; 173(5):1540-50. PubMed ID: 18832579
[TBL] [Abstract][Full Text] [Related]
40. Vascular endothelial growth factor C enhances cervical cancer migration and invasion via activation of focal adhesion kinase.
Chen H; Suo K; Cheng Y; Zheng B; Xu L
Gynecol Endocrinol; 2013 Jan; 29(1):20-4. PubMed ID: 22817694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]